本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 中国天楹股份有限公司（以下简称"公司"）于 2025 年 8 月 21 日召开第九 届董事会第十二次会议，审议并通过了《关于注销部分回购股份并减少注册资本 的议案》，同意将回购专用证券账户中的 112,750,413 股公司股票予以注销。本 次回购股份注销完成后，公司股份总数将由 2,500,783,182 股变更为 2,388,032,769 股。公司注册资本也将由 2,500,783,182 元变更为 2,388,032,769 元。本次回购股 份注销事项尚需提交公司 2025 年第二次临时股东会审议。现将具体情况公告如 下： 一、回购股份的实施情况 公司于 2021 年 11 月 11 日召开第八届董事会第十二次会议，审议通过了《关 于回购公司股份方案的议案》，并于 2021 年 11 月 13 日披露了《关于回购公司 股份的报告书》，公司拟以自有资金回购公司股份，回购的资金总额不低于人民 币 8 亿元（含）且不超过人民币 15 亿元（含），回购股份价格不超过人民币 6.50 元/股（含），回购期限为自公司 ...

Core Viewpoint - Shanghai Cambridge Technology Co., Ltd. has completed the registration of changes in its business license, reflecting a reduction in registered capital and adjustments to its governance structure following the implementation of a restricted stock incentive plan [1][2]. Group 1: Business Changes - The company held two extraordinary general meetings on November 30, 2022, and June 16, 2025, to approve the stock incentive plan and the reduction of registered capital [1]. - The total share capital has been reduced from 268,041,841 shares to 268,019,841 shares, and the registered capital has decreased from RMB 268,041,841 to RMB 268,019,841 [2]. Group 2: Shareholder Information - Cambridge Industries Company Limited, the controlling shareholder, held 36,556,453 shares (13.64% of total shares) before the changes, while Shanghai Kangling Technology Partnership held 5,918,476 shares (2.21%) [7]. - After the changes, the combined shareholding of the information disclosure obligors decreased from 15.85% to 15.00% of the total shares [8][10]. Group 3: Future Plans - The information disclosure obligors have no plans to increase their shareholding in the next 12 months [10]. - A reduction plan was disclosed on May 13, 2025, allowing for a maximum reduction of 8,041,254 shares (2.00% of total shares) within three months [11].

Group 1 - The company plans to change the purpose of repurchased A-shares from employee stock ownership plan to cancellation and reduction of registered capital, involving the cancellation of 67,786,990 shares [1] - After the cancellation, the company's total share capital is expected to be reduced, with specific details provided in the announcement dated August 19, 2025 [1] - The company is also proposing amendments to its Articles of Association in accordance with relevant laws and regulations due to changes in registered capital [2]

Group 1 - The company has changed the purpose of its share repurchase plan, now intending to use the repurchased shares for capital reduction instead of employee stock ownership plans [1] - A total of 6,379,004 shares will be canceled, leading to a corresponding reduction in the company's registered capital [2] - The final situation of the company's capital changes will be confirmed by the China Securities Depository and Clearing Corporation after the completion of the cancellation process [2] Group 2 - The company is notifying creditors about the capital reduction, allowing them to claim their debts within 45 days from the announcement [2] - Creditors must provide relevant documentation to assert their claims, including contracts and proof of debt relationships [3] - Specific requirements for both corporate and individual creditors are outlined for submitting claims [3]

Core Viewpoint - The company, Buchang Pharma, is demonstrating long-term confidence in its value by announcing the cancellation of repurchased shares, which reflects its commitment to shareholder returns and social responsibility [1][2]. Group 1: Share Repurchase and Cancellation - Buchang Pharma plans to cancel 51,474,203 repurchased shares, which accounts for 4.65% of the total shares before cancellation, reducing the total share capital from 1,106,042,645 to 1,054,568,442 shares [1]. - Since its listing, the company has conducted three share repurchases, totaling 87,012,200 shares and spending 1,744.43 million yuan, with 35,538,000 shares already canceled [2]. - The cancellation of shares is expected to enhance earnings per share and net asset value, stabilize stock prices, and reflect the company's financial health and cash flow [2]. Group 2: Financial Performance and Shareholder Returns - The company has approved a mid-term dividend plan for 2025, reinforcing its commitment to returning value to shareholders, with cumulative dividends exceeding 7.5 billion yuan since its establishment [2]. - Buchang Pharma has paid over 32 billion yuan in taxes and has contributed to local economic development through job creation [3]. Group 3: Industry Position and Product Development - With over 30 years in the traditional Chinese medicine sector, Buchang Pharma has developed a diversified portfolio across various pharmaceutical categories, becoming a leading innovator in traditional Chinese medicine [4]. - The company holds 468 valid patents and is advancing 213 research projects, focusing on major diseases and cultivating significant products [4]. - Recent international approvals for products like the "Stabilizing Heart Granules" in Malaysia and "Pulmonary Detox Granules" in Canada, Kazakhstan, and Uzbekistan indicate the company's global expansion efforts [5]. Group 4: Vision and Social Responsibility - Buchang Pharma aims to be "China's Johnson & Johnson, and the world's Buchang," emphasizing its commitment to social responsibility and innovation in the healthcare sector [5].

证券代码：603158 证券简称：腾龙股份 公告编号：2025-041 二、需债权人知晓的相关信息 由于公司本次回购注销部分股权激励股份将导致注册资本减少，根据《中华 人民共和国公司法》等相关规定，公司债权人自接到公司通知起30日内、未接到 通知者自本公告披露之日起45日内向本公司申报债权，并有权凭有效债权文件及 相关凭证要求公司清偿债务或者提供相应担保。债权人如逾期未向公司申报债权， 不会因此影响其债权的有效性，相关债务义务将由公司根据原债权文件的约定继 续履行。公司本次回购注销将按法定程序继续实施。 公司债权人如要求公司清偿债务或提供相应担保的，应根据《中华人民共和 国公司法》等法律、法规的有关规定向公司提出书面要求，并随附有关证明文件。 债权人可采用信函或传真的方式申报，债权申报所需材料：公司债权人可持证明 债权债务关系存在的合同、协议及其他凭证的原件及复印件到公司申报债权。债 权人为法人的，需同时携带法人营业执照副本原件及复印件、法定代表人身份证 明文件；委托他人申报的，除上述文件外，还需携带法定代表人授权委托书和代 理人有效身份证的原件及复印件。债权人为自然人的，需同时携带有效身份证的 原件及复印件 ...

Core Viewpoint - The company will cancel 51,474,203 repurchased shares, accounting for 4.65% of the total shares before cancellation, reducing the total share capital from 1,106,042,645 shares to 1,054,568,442 shares after the cancellation [2][7]. Group 1: Share Repurchase and Cancellation Details - The company approved a share repurchase plan on December 13, 2023, with a total fund of no less than 180 million yuan and no more than 360 million yuan, with a maximum repurchase price of 24 yuan per share [3]. - The repurchase amount was later increased to between 360 million yuan and 720 million yuan, with the company completing the repurchase by November 6, 2024, acquiring 44,853,573 shares at an average price between 14.16 yuan and 17.44 yuan, totaling approximately 712.38 million yuan [3][4]. - A second repurchase plan was approved on December 26, 2024, with a total fund of no less than 50 million yuan and no more than 100 million yuan, with a maximum price of 23 yuan per share, resulting in the acquisition of 6,620,630 shares by May 9, 2025, at prices between 13.86 yuan and 15.07 yuan, totaling approximately 98.06 million yuan [4]. Group 2: Approval and Legal Compliance - The cancellation of repurchased shares was approved in meetings held on April 25 and May 26, 2025, with the purpose of reducing registered capital [5]. - The company will follow relevant laws and regulations for the cancellation process, with the cancellation expected to be completed on August 12, 2025 [7]. - The company has notified creditors regarding the cancellation, and no requests for early debt repayment or guarantees were received within the stipulated period [7].

关于注销回购股份的实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603858 证券简称：步长制药 公告编号：2025-145 山东步长制药股份有限公司 重要内容提示： ●公司将注销 51,474,203 股已回购股份，占注销前公司总股本的比例为 ●回购股份注销日期：2025 年 8 月 12 日 一、股份回购方案及实施情况 山东步长制药股份有限公司（以下简称"公司"）于 2023 年 12 月 13 日召 开第四届董事会第四十七次会议，审议通过了《关于以集中竞价交易方式回购股 份的方案的议案》，同意公司使用自有资金以集中竞价交易方式回购社会公众股 份。本次回购的资金总额不低于 1.80 亿元，不高于 3.60 亿元，回购价格上限为 票的公司债券。公司于 2024 年 6 月 14 日召开第四届董事会第五十六次会议，审 议通过了《关于增加股份回购金额的议案》，同意股份回购金额由原来 1.80-3.60 亿元增加至 3.60-7.20 亿元，原回购股份的方案中其他内容不变。截至 2024 年 股份 44,85 ...

Group 1 - The company has decided to cancel 10,000,053 repurchased shares and reduce its registered capital by the same amount, following the approval from the board and shareholders [1] - The cancellation of shares is due to the expiration of the three-year holding period for the repurchased shares, during which the company did not implement any employee stock ownership or incentive plans [1] - The company is complying with relevant laws and regulations regarding share repurchase and capital reduction [1] Group 2 - Creditors have the right to request debt repayment or guarantees within 45 days from the announcement date, with specific procedures outlined for submitting claims [2] - The company has provided contact information and requirements for creditors to submit their claims, including necessary documentation [2][3] - The announcement emphasizes that the validity of creditors' claims will not be affected if they fail to apply within the specified period [2]

Core Viewpoint - Xinjiang Tianrun Dairy Co., Ltd. plans to cancel 4,799,955 shares, which represents a reduction of approximately 1.50% of the total share capital before cancellation, amounting to 320,212,773 shares [2][3] Summary of Share Repurchase - The company approved a share repurchase plan to buy back shares using its own funds for employee stock ownership plans or equity incentives, with a maximum repurchase price of RMB 15.00 per share and a total repurchase quantity between 3,200,000 and 4,800,000 shares [2] - The average repurchase price was RMB 12.776 per share, with the highest price at RMB 13.50 and the lowest at RMB 11.78, totaling a fund usage of RMB 61,000,000 [3] Decision Process for Share Cancellation - The decision to cancel the repurchased shares was approved in meetings held on June 5, 2025, and June 24, 2025, where the purpose of the repurchased shares was changed from employee stock ownership to cancellation and reduction of registered capital [3][4] - The company has followed legal procedures to notify creditors regarding the share cancellation, and no objections were raised by creditors [3] Arrangement for Share Cancellation - The cancellation of shares is expected to be completed by August 12, 2025, after which the company will proceed with necessary registration changes [4] Impact on Company’s Capital Structure - Following the cancellation, the total share capital will decrease to 315,412,818 shares, with the number of unrestricted circulating shares adjusted accordingly [5][6] - The cancellation is not expected to significantly impact the company's financial status, operational results, or shareholder equity, nor will it affect the company's compliance with listing conditions [6]